Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory Board. Dr. Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research. He is currently leading a new National Health Service...

    2021-08-25 8:00 AM EDT
  • Entheon Biomedical Corp. Announces DTC Eligibility

    Vancouver, British Columbia--(Newsfile Corp. - August 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.The DTC is the largest securities depository in the world and facilitates electronic settlement of stock certificate transfers in the United States....

    2021-08-24 8:00 AM EDT
  • Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

    Vancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, today announced the sponsorship of a clinical research study with Heading Health LLC ("Heading Health") as institution and Dr. Steve Levine, MD, as principal investigator to determine the electroneurophysiologic effects of ketamine.Entheon previously announced its business arrangement with Heading Health on January 4, 2021, a psychiatric clinic...

    2021-08-12 8:00 AM EDT
  • Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. ("Lobo"), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive drugs. Further to the Company's news release dated June 16, 2021 (the "Initial...

    2021-07-30 8:00 AM EDT
  • Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

    Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta. Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of the Canadian College of Neuropsychopharmacology (CCNP),...

    2021-07-28 8:00 AM EDT
  • Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emergency physician and addiction specialist, Dr. Dinesh Bayana as a medical advisor, providing expertise on the development of the Company's DMT clinical program as it relates to patient care in the context of addiction medicine.As an emergency and addiction medicine...

    2021-06-30 8:30 AM EDT
  • Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness

    Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC ("Maya'') to help drive brand awareness of the Company's Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").Maya has developed a measurement-based care platform designed to support psychedelic practitioners and patients....

    2021-06-25 8:30 AM EDT
  • Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with 3W Wellness Inc. ("Third Wave'') to help drive brand awareness of the company's Psychedelics Genetic Test kit, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").The agreement with Third Wave - an organization committed to sharing trusted, research-based content and...

    2021-06-22 8:30 AM EDT